Fischer Medical Ventures Ltd and Nervotec Partnership: Revolutionizing Healthcare

On July 01, 2024, Fischer Medical Ventures Limited (formerly Fischer Chemic Limited) is excited to announce a successful partnership with Nervotec Pte Ltd, a Singapore-based innovator. Together, they aim to enable blood pressure, haemoglobin, and HbA1C screening using camera-enabled devices.

This collaboration represents a significant step in healthcare screening, using advanced, contactless video-based technology to monitor vital signs.

Technology Description

Nervotec, based in Singapore, revolutionises healthcare with its contactless solution that doesn’t require wearables. Using remote photoplethysmography (rPPG) and AI, Nervotec measures vital signs like heart rate, respiration rate, oxygen levels, and even blood pressure using a camera-equipped device such as a smartphone or laptop.

This technology provides fast, accurate, and cost-effective health assessments, eliminating the need for traditional wearables or invasive tests. Recently, Nervotec achieved a global first by adding hemoglobin and HbA1C measurements to its capabilities, which previously required blood samples and significant time. This breakthrough makes comprehensive health monitoring possible within minutes.

Impact on Healthcare

The partnership between Fischer MVL and Nervotec represents a significant advancement in healthcare screening, offering accessible, efficient, and comprehensive solutions. By combining Fischer MVL’s expertise in medical devices and global reach with Nervotec’s cutting-edge technologies, this collaboration aims to redefine healthcare delivery worldwide.

Commenting on the announcement, Mr Ravindran Govindan, Chairman and Managing Director of Fischer MVL, expressed his enthusiasm about the collaboration: “We are elated to partner with Nervotec, a pioneer and leader in contactless vital signs monitoring that will redefine healthcare delivery worldwide. Not everyone has wearables, but most of us have a camera phone to enable Nervotec’s technology to regularly monitor our own health and support mass screening faster and more cost-effectively. We are excited about the potential of rPPG technology beyond HbA1C to detect irregular heartbeats and cardiovascular disease, combined with blood pressure and blood sugar levels, to determine the overall health of individuals worldwide. Nervotec’s solutions complement our portfolio of medical devices and diagnostic solutions and will create great value for our customers and stakeholders.”

Mr Jonathan Lau, Co-founder and CEO of Nervotec, emphasised the transformative potential of their technology, “With the high prevalence of undetected conditions such as hypertension and diabetes, we believe Nervotec’s innovative solution can truly make a difference in the well-being of billions of people globally. By identifying health risks before they escalate, Nervotec’s technology empowers individuals, healthcare providers, and employers to take timely action. This partnership with Fischer MVL enables us to expand our reach and deliver impactful health insights across various sectors, from workplace safety to personalised healthcare.”

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.